Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
Paz-Ares, L Socinski, M Shahidi, J Hozak, R Soldatenkova, V Kurek, R Varella-Garcia, M Thatcher, Nick Hirsch, F
Paz-Ares, L
Socinski, M
Shahidi, J
Hozak, R
Soldatenkova, V
Kurek, R
Varella-Garcia, M
Thatcher, Nick
Hirsch, F
Citations
Altmetric:
Abstract
SQUIRE demonstrated addition of necitumumab to gemcitabine and cisplatin significantly improved survival in patients with stage IV sq-NSCLC. Here we report additional outcomes for the sub-population of patients with tumor EGFR protein expression.
Description
Date
2016-05-20
Publisher
Collections
Keywords
Type
Article
Citation
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. 2016: Ann Oncol